Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Gynecology

  Free Subscription


Articles published in Clin Cancer Res

Retrieve available abstracts of 87 articles:
HTML format



Single Articles


    August 2022
  1. MILLER KM, Friedman CF
    Bifunctional Blockade: A Novel Immunotherapy Approach for Cervical Cancer.
    Clin Cancer Res. 2022 Aug 10. pii: 707611. doi: 10.1158/1078-0432.CCR-22-1779.
    PubMed     Abstract available


  2. SERRA V, Wang AT, Castroviejo-Bermejo M, Polanska UM, et al
    Identification of a molecularly-defined subset of breast and ovarian cancer models that respond to WEE1 or ATR inhibition, overcoming PARP inhibitor resistance.
    Clin Cancer Res. 2022 Aug 3. pii: 707431. doi: 10.1158/1078-0432.CCR-22-0568.
    PubMed     Abstract available


  3. SINGER CF, Holst F, Steurer S, Burandt EC, et al
    Estrogen Receptor Alpha Gene Amplification Is an Independent Predictor of Long-Term Outcome in Postmenopausal Patients with Endocrine-Responsive Early Breast Cancer.
    Clin Cancer Res. 2022 Aug 3:OF1-OF9. doi: 10.1158/1078-0432.CCR-21-4328.
    PubMed     Abstract available


  4. LEE JM, Moore RG, Ghamande S, Park MS, et al
    Cediranib in combination with olaparib in patients without a germline BRCA1/2 mutation and with recurrent platinum-resistant ovarian cancer: Phase IIb CONCERTO trial.
    Clin Cancer Res. 2022 Aug 2. pii: 707411. doi: 10.1158/1078-0432.CCR-21-1733.
    PubMed     Abstract available


    July 2022
  5. MANNING-GEIST BL, Liu YL, Devereaux KA, Da Cruz Paula A, et al
    Microsatellite instability-high endometrial cancers with MLH1 promoter hypermethylation have distinct molecular and clinical profiles.
    Clin Cancer Res. 2022 Jul 18. pii: 707055. doi: 10.1158/1078-0432.CCR-22-0713.
    PubMed     Abstract available


  6. BOLTON KL, Chen D, Corona de la Fuente RI, Fu Z, et al
    Molecular subclasses of clear cell ovarian carcinoma and their impact on disease behavior and outcomes.
    Clin Cancer Res. 2022 Jul 11. pii: 706955. doi: 10.1158/1078-0432.CCR-21-3817.
    PubMed     Abstract available


  7. MARIN-JIMENEZ JA, Garcia-Mulero S, Matias-Guiu X, Piulats JM, et al
    Facts and hopes in immunotherapy of endometrial cancer.
    Clin Cancer Res. 2022 Jul 5. pii: 706852. doi: 10.1158/1078-0432.CCR-21-1564.
    PubMed     Abstract available


    June 2022
  8. NOH JJ, Cho YJ, Ryu JY, Choi JJ, et al
    Anti-cancer activity of the combination of cabozantinib and temozolomide in uterine sarcoma.
    Clin Cancer Res. 2022 Jun 21. pii: 705009. doi: 10.1158/1078-0432.CCR-22-0985.
    PubMed     Abstract available


  9. JOHNSON M, Dudek AZ, Sukari A, Call J, et al
    ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study.
    Clin Cancer Res. 2022;28:2517-2526.
    PubMed     Abstract available


  10. HOLLIS RL, Meynert AM, Michie CO, Rye T, et al
    Multiomic characterisation of high grade serous ovarian carcinoma enables high resolution patient stratification.
    Clin Cancer Res. 2022 Jun 13. pii: 704888. doi: 10.1158/1078-0432.CCR-22-0368.
    PubMed     Abstract available


  11. XU J, Fang Y, Chen K, Li S, et al
    Single-cell RNA sequencing reveals the tissue architecture in human high-grade serous ovarian cancer.
    Clin Cancer Res. 2022 Jun 8. pii: 704811. doi: 10.1158/1078-0432.CCR-22-0296.
    PubMed     Abstract available


  12. FENG J, Tang D, Wang J, Zhou Q, et al
    SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF-beta, for recurrent or metastatic cervical cancer: a clinical expansion cohort of phase 1 study.
    Clin Cancer Res. 2022 Jun 2. pii: 699316. doi: 10.1158/1078-0432.CCR-22-0346.
    PubMed     Abstract available


  13. BYCHKOVSKY BL, Li T, Sotelo J, Tayob N, et al
    Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program.
    Clin Cancer Res. 2022;28:2349-2360.
    PubMed     Abstract available


  14. NICUM S, Blagden SP
    PARPs: All for One and One for All? Enhancing Diversity in Clinical Trials.
    Clin Cancer Res. 2022;28:2201-2203.
    PubMed     Abstract available


    May 2022
  15. ARANDA F, Eguren-Santamaria I, Bella A, Berraondo P, et al
    Revisiting Intracavitary Immunotherapy of Cancer.
    Clin Cancer Res. 2022;28:1993-1995.
    PubMed     Abstract available


  16. FUCIKOVA J, Hensler M, Kasikova L, Lanickova T, et al
    An autologous dendritic cell vaccine promotes anticancer immunity in ovarian cancer patients with low mutational burden and cold tumors.
    Clin Cancer Res. 2022 May 10. pii: 696491. doi: 10.1158/1078-0432.CCR-21-4413.
    PubMed     Abstract available


    April 2022
  17. YANG SYC, Pugh TJ, Oza AM
    Double trouble: whole genome doubling distinguishes early from late ovarian cancer.
    Clin Cancer Res. 2022 Apr 27. pii: 694785. doi: 10.1158/1078-0432.CCR-22-0336.
    PubMed     Abstract available


  18. MANNING-GEIST B, Gordhandas S, Liu YL, Zhou Q, et al
    MAPK pathway genetic alterations are associated with prolonged overall survival in low-grade serous ovarian carcinoma.
    Clin Cancer Res. 2022 Apr 20. pii: 694634. doi: 10.1158/1078-0432.CCR-21-4183.
    PubMed     Abstract available


  19. LIU M, Tayob N, Penter L, Sellars M, et al
    Improved T cell immunity following neoadjuvant chemotherapy in ovarian cancer.
    Clin Cancer Res. 2022 Apr 20. pii: 694633. doi: 10.1158/1078-0432.CCR-21-2834.
    PubMed     Abstract available


  20. CHENG Z, Mirza H, Ennis DP, Smith P, et al
    The Genomic Landscape of Early-Stage Ovarian High-Grade Serous Carcinoma.
    Clin Cancer Res. 2022 Apr 10:OF1-OF12. doi: 10.1158/1078-0432.CCR-21-1643.
    PubMed     Abstract available


  21. LIM JSJ, Wong ALA, Ow SGW, Ngoi NYL, et al
    Phase Ib/II dose expansion study of lenvatinib combined with letrozole in post-menopausal women with hormone receptor positive breast cancer.
    Clin Cancer Res. 2022 Apr 1. pii: 694118. doi: 10.1158/1078-0432.CCR-21-4179.
    PubMed     Abstract available


  22. AREND RC, Scalise CB, Gordon ER, Davis AM, et al
    Metabolic Alterations and WNT Signaling Impact Immune Response in HGSOC.
    Clin Cancer Res. 2022;28:1433-1445.
    PubMed     Abstract available


    March 2022
  23. YOSHIDA K, Yokoi A, Yamamoto T, Hayashi Y, et al
    Aberrant activation of cell cycle-related kinases and the potential therapeutic impact of PLK1 or CHEK1 inhibition in uterine leiomyosarcoma.
    Clin Cancer Res. 2022 Mar 18. pii: 682165. doi: 10.1158/1078-0432.CCR-22-0100.
    PubMed     Abstract available


  24. VAN DEN HELDER R, Steenbergen RDM, van Splunter AP, Mom CH, et al
    HPV AND DNA METHYLATION TESTING IN URINE FOR CERVICAL INTRAEPITHELIAL NEOPLASIA AND CERVICAL CANCER DETECTION.
    Clin Cancer Res. 2022 Mar 10. pii: 682143. doi: 10.1158/1078-0432.CCR-21-3710.
    PubMed     Abstract available


    February 2022
  25. DIGKLIA A, Coukos G, Homicsko K
    Trabectedin and Durvalumab Combination is Feasible - and Active in Relapsing Ovarian Cancer.
    Clin Cancer Res. 2022 Feb 17. pii: 681578. doi: 10.1158/1078-0432.CCR-21-4592.
    PubMed     Abstract available


  26. GAO Q, Zhu J, Zhao W, Huang Y, et al
    Olaparib Maintenance Monotherapy in Asian Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Phase III Trial (L-MOCA).
    Clin Cancer Res. 2022 Feb 7. pii: 1078-0432.CCR-21-3023.
    PubMed     Abstract available


  27. SERRITELLA AV, Shevrin D, Heath EI, Wade JL, et al
    Phase I/II trial of enzalutamide and mifepristone, a glucocorticoid receptor antagonist, for metastatic castration-resistant prostate cancer.
    Clin Cancer Res. 2022 Feb 2. pii: 1078-0432.CCR-21-4049.
    PubMed     Abstract available


    January 2022
  28. ORR B, Mahdi H, Fang Y, Strange M, et al
    Phase I trial combining chemokine-targeting with loco-regional chemo-immunotherapy for recurrent, platinum-sensitive ovarian cancer shows induction of CXCR3 ligands and markers of type 1 immunity.
    Clin Cancer Res. 2022 Jan 19. pii: 1078-0432.CCR-21-3659.
    PubMed     Abstract available


  29. VOUGIOUKLAKIS T, Zhu K, Vasudevaraja V, Serrano J, et al
    Integrated analysis of ovarian juvenile granulosa cell tumors reveals distinct epigenetic signatures and recurrent TERT rearrangements.
    Clin Cancer Res. 2022 Jan 14. pii: 1078-0432.CCR-21-3394.
    PubMed     Abstract available


  30. GARCIA-SAENZ JA, Martinez-Janez N, Cubedo R, Jerez Y, et al
    Sapanisertib Plus Fulvestrant in Post-Menopausal Women with Estrogen Receptor-Positive/HER2-Negative Advanced Breast Cancer After Progression on Aromatase Inhibitor.
    Clin Cancer Res. 2022 Jan 3. pii: 1078-0432.CCR-21-2652.
    PubMed     Abstract available


    December 2021
  31. TOULMONDE M, Brahmi M, Giraud A, Chakiba C, et al
    Trabectedin plus durvalumab in patients with advanced pretreated soft tissue sarcoma and ovarian carcinoma (TRAMUNE): an open-label, multicenter phase Ib study.
    Clin Cancer Res. 2021 Dec 29. pii: 1078-0432.CCR-21-2258.
    PubMed     Abstract available


  32. SHARMA SK, Mack KN, Piersigilli A, Pourat J, et al
    ImmunoPET of Ovarian and Pancreatic Cancer with AR9.6, a Novel MUC16-Targeted Therapeutic Antibody.
    Clin Cancer Res. 2021 Dec 14. pii: 1078-0432.CCR-21-1798.
    PubMed     Abstract available


    November 2021
  33. WU X, Zhu J, Wang J, Lin ZQ, et al
    Pamiparib Monotherapy for Patients With Germline BRCA1/2-Mutated Ovarian Cancer Previously Treated With at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study.
    Clin Cancer Res. 2021 Nov 29. pii: 1078-0432.CCR-21-1186.
    PubMed     Abstract available


  34. VAN DER WIJNGAART H, Hoes LR, van Berge Henegouwen JM, van der Velden DL, et al
    Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types.
    Clin Cancer Res. 2021;27:6106-6114.
    PubMed     Abstract available


    October 2021
  35. ARORA S, Narayan P, Ison G, Berman T, et al
    U.S. FDA Drug Approvals for Gynecological Malignancies - A Decade in Review.
    Clin Cancer Res. 2021 Oct 28. pii: 1078-0432.CCR-21-2599.
    PubMed     Abstract available


  36. MOORE KN, Chambers SK, Hamilton EP, Chen LM, et al
    Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: an Open-Label, Four-Arm, Phase II Study.
    Clin Cancer Res. 2021 Oct 13. pii: 1078-0432.CCR-21-0158.
    PubMed     Abstract available


  37. TIAN L, Xu B, Teng KY, Song M, et al
    Targeting Fc receptor-mediated effects and the "don't eat me" signal with an oncolytic virus expressing an anti-CD47 antibody to treat metastatic ovarian cancer.
    Clin Cancer Res. 2021 Oct 13. pii: 1078-0432.CCR-21-1248.
    PubMed     Abstract available


    September 2021
  38. SCHOUTEN PC, Richters LK, Vis DJ, Kommoss S, et al
    Ovarian cancer specific BRCA-like copy number aberration classifiers detect mutations associated with homologous recombination deficiency in the AGO-TR1 trial.
    Clin Cancer Res. 2021 Sep 30. pii: 1078-0432.CCR-21-1673.
    PubMed     Abstract available


  39. ROCKALL AG, Barwick TD, Wilson W, Singh N, et al
    DIAGNOSTIC ACCURACY OF FEC-PET/CT, FDG-PET/CT AND DIFFUSION-WEIGHTED MRI IN DETECTION OF NODAL METASTASES IN SURGICALLY TREATED ENDOMETRIAL AND CERVICAL CARCINOMA.
    Clin Cancer Res. 2021 Sep 15. pii: 1078-0432.CCR-21-1834.
    PubMed     Abstract available


  40. CECIL DL, Liao JB, Dang Y, Coveler AL, et al
    Immunization with a plasmid DNA vaccine encoding the N-terminus of Insulin like Growth Factor Binding Protein-2 in advanced ovarian cancer leads to high level Type I immune responses.
    Clin Cancer Res. 2021 Sep 15. pii: 1078-0432.CCR-21-1579.
    PubMed     Abstract available


  41. WESTIN SN, Labrie M, Litton JK, Blucher A, et al
    Phase 1b dose expansion and translational analyses of olaparib in combination with capivasertib in recurrent endometrial, triple negative breast, and ovarian cancer.
    Clin Cancer Res. 2021 Sep 13. pii: 1078-0432.CCR-21-1656.
    PubMed     Abstract available


  42. DO KT, Kochupurakkal B, Kelland S, de Jonge A, et al
    Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors.
    Clin Cancer Res. 2021;27:4710-4716.
    PubMed     Abstract available


    August 2021
  43. MAITLAND ML, Sachdev JC, Sharma MR, Moreno V, et al
    First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors.
    Clin Cancer Res. 2021;27:4511-4520.
    PubMed     Abstract available


  44. SZTUPINSZKI Z, Diossy M, Borcsok J, Prosz A, et al
    Comparative Assessment of Diagnostic Homologous Recombination Deficiency associated mutational signatures in ovarian cancer.
    Clin Cancer Res. 2021 Aug 11. pii: 1078-0432.CCR-21-0981.
    PubMed     Abstract available


  45. SOOD AK, Fletcher MS, Gruman LM, Coffin JE, et al
    Editor's Note: The Paradoxical Expression of Maspin in Ovarian Carcinoma.
    Clin Cancer Res. 2021;27:4456.
    PubMed    


  46. KAMAT AA, Fletcher M, Gruman LM, Mueller P, et al
    Editor's Note: The Clinical Relevance of Stromal Matrix Metalloproteinase Expression in Ovarian Cancer.
    Clin Cancer Res. 2021;27:4455.
    PubMed    


  47. MANGALA LS, Zuzel V, Schmandt R, Leshane ES, et al
    Editor's Note: Therapeutic Targeting of ATP7B in Ovarian Carcinoma.
    Clin Cancer Res. 2021;27:4454.
    PubMed    


  48. KIM HS, Han HD, Armaiz-Pena GN, Stone RL, et al
    Editor's Note: Functional Roles of Src and Fgr in Ovarian Carcinoma.
    Clin Cancer Res. 2021;27:4452.
    PubMed    


  49. MORENO-SMITH M, Lu C, Shahzad MMK, Pena GNA, et al
    Editor's Note: Dopamine Blocks Stress-mediated Ovarian Carcinoma Growth.
    Clin Cancer Res. 2021;27:4451.
    PubMed    


  50. MATSUO K, Nishimura M, Bottsford-Miller JN, Huang J, et al
    Editor's Note: Targeting Src in Mucinous Ovarian Carcinoma.
    Clin Cancer Res. 2021;27:4450.
    PubMed    


  51. ROH JW, Huang J, Hu W, Yang X, et al
    Editor's Note: Biologic Effects of Platelet-Derived Growth Factor Receptor alpha Blockade in Uterine Cancer.
    Clin Cancer Res. 2021;27:4449.
    PubMed    


  52. WILLIAMSON CW, Zamarin D, Mayadev J
    Standardized Uptake Value Illuminates Tumor Inflammation and Treatment Response.
    Clin Cancer Res. 2021;27:4136-4138.
    PubMed     Abstract available


    July 2021
  53. THAKER PH, Bradley WH, Leath CA, Gunderson Jackson C, et al
    GEN-1 in Combination with Neoadjuvant Chemotherapy for Patients with Advanced Epithelial Ovarian Cancer: A Phase I Dose-Escalation Study.
    Clin Cancer Res. 2021 Jul 29. pii: 1078-0432.CCR-21-0360.
    PubMed     Abstract available


  54. MONDINI M, Deutsch E
    (Chemo)Radiotherapy-Immunotherapy Combinations: Time to Get Tailored?
    Clin Cancer Res. 2021;27:3815-3817.
    PubMed     Abstract available


  55. JEANNOT E, Latouche A, Bonneau C, Calmejane MA, et al
    Circulating HPV DNA as a marker for early detection of relapse in patients with cervical cancer.
    Clin Cancer Res. 2021 Jul 1. pii: 1078-0432.CCR-21-0625.
    PubMed     Abstract available


    June 2021
  56. THOMPSON PA, Huang C, Yang J, Wertheim BC, et al
    Sulindac, a non-selective NSAID, reduces breast density in postmenopausal women with breast cancer treated with aromatase inhibitors.
    Clin Cancer Res. 2021 Jun 10. pii: 1078-0432.CCR-21-0732.
    PubMed     Abstract available


    May 2021
  57. KANDIMALLA R, Wang W, Yu F, Zhou N, et al
    OCaMIR - A noninvasive, diagnostic signature for early stage ovarian cancer: a multi-cohort retrospective and prospective study.
    Clin Cancer Res. 2021 May 25. pii: 1078-0432.CCR-21-0267.
    PubMed     Abstract available


  58. MIAO YR, Thakkar KN, Qian J, Kariolis MS, et al
    Neutralization of PD-L2 is Essential for Overcoming Immune Checkpoint Blockade Resistance in Ovarian Cancer.
    Clin Cancer Res. 2021 May 19. pii: 1078-0432.CCR-20-0482.
    PubMed     Abstract available


  59. LAUMONT CM, Wouters MCA, Smazynski J, Gierc NS, et al
    Single-cell profiles and prognostic impact of tumor-infiltrating lymphocytes co-expressing CD39, CD103, and PD-1 in ovarian cancer.
    Clin Cancer Res. 2021 May 7. pii: 1078-0432.CCR-20-4394.
    PubMed     Abstract available


    April 2021
  60. FERRALL L, Lin KY, Roden RBS, Hung CF, et al
    Cervical Cancer Immunotherapy: Facts and Hopes.
    Clin Cancer Res. 2021 Apr 22. pii: 1078-0432.CCR-20-2833.
    PubMed     Abstract available


  61. FLOBERG JM, Zhang J, Muhammad N, DeWees TA, et al
    Standardized Uptake Value for 18F-Fluorodeoxyglucose is a Marker of Inflammatory State and Immune Infiltrate in Cervical Cancer.
    Clin Cancer Res. 2021 Apr 5. pii: 1078-0432.CCR-20-4450.
    PubMed     Abstract available


    March 2021
  62. THIBODEAUX S, Barnett B, Pandeswara S, Wall S, et al
    Interferon-alpha augments clinical efficacy of regulatory T cell depletion with denileukin diftitox in ovarian cancer.
    Clin Cancer Res. 2021 Mar 26. pii: 1078-0432.CCR-20-4594.
    PubMed     Abstract available


  63. CHEN J, Chen C, Zhan Y, Zhou L, et al
    Heterogeneity of interferon-mediated responses and tumor immunogenicity in cervical cancer patients receiving concurrent chemoradiotherapy.
    Clin Cancer Res. 2021 Mar 25. pii: 1078-0432.CCR-20-4521.
    PubMed     Abstract available


  64. DUSKA LR, Filiaci VL, Walker JL, Holman LL, et al
    A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response.
    Clin Cancer Res. 2021 Mar 25. pii: 1078-0432.CCR-20-4618.
    PubMed     Abstract available


  65. KAZMI F, Nicum S, Roux RL, Spiers L, et al
    A Phase IB open-label, dose-escalation study of NUC1031 in combination with carboplatin for recurrent ovarian cancer.
    Clin Cancer Res. 2021 Mar 19. pii: 1078-0432.CCR-20-4403.
    PubMed     Abstract available


  66. EWING A, Meynert A, Churchman M, Grimes G, et al
    Structural variants at the BRCA1/2 loci are a common source of homologous repair deficiency in high grade serous ovarian carcinoma.
    Clin Cancer Res. 2021 Mar 19. pii: 1078-0432.CCR-20-4068.
    PubMed     Abstract available


    February 2021
  67. MOMENI-BOROUJENI A, Dahoud W, Vanderbilt CM, Chiang S, et al
    Clinicopathologic and Genomic Analysis of TP53-Mutated Endometrial Carcinomas.
    Clin Cancer Res. 2021 Feb 18. pii: 1078-0432.CCR-20-4436.
    PubMed     Abstract available


  68. LI N, Bu H, Liu J, Zhu J, et al
    An open-label, multi-center, single-arm, phase 2 study of fluzoparib in patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian cancer.
    Clin Cancer Res. 2021 Feb 8. pii: 1078-0432.CCR-20-3546.
    PubMed     Abstract available


    January 2021
  69. HONG B, Chapa V, Saini U, Modgil P, et al
    Oncolytic HSV Therapy Modulates Vesicular Trafficking Inducing Cisplatin Sensitivity and Antitumor Immunity.
    Clin Cancer Res. 2021;27:542-553.
    PubMed     Abstract available


  70. HU Z, Cunnea P, Zhong Z, Lu H, et al
    The Oxford Classic Links Epithelial-to-Mesenchymal Transition to Immunosuppression in Poor Prognosis Ovarian Cancers.
    Clin Cancer Res. 2021 Jan 14. pii: 1078-0432.CCR-20-2782.
    PubMed     Abstract available


    December 2020
  71. PARACCHINI L, Beltrame L, Grassi T, Inglesi A, et al
    Genome-wide copy number alterations in circulating tumor DNA as a novel biomarker in high grade serous ovarian cancer patients.
    Clin Cancer Res. 2020 Dec 15. pii: 1078-0432.CCR-20-3345.
    PubMed     Abstract available


    October 2020
  72. GUERINI-ROCCO E, Gray KP, Fumagalli C, Reforgiato MR, et al
    Genomic aberrations and late recurrence in postmenopausal women with hormone receptor-positive early breast cancer: Results from the SOLE Trial.
    Clin Cancer Res. 2020 Oct 20. pii: 1078-0432.CCR-20-0126.
    PubMed     Abstract available


    September 2020
  73. BARDIA A, Modi S, Oliveira M, Cortes J, et al
    Phase 1b Dose Escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women With HR+, HER2- Advanced Breast Cancer.
    Clin Cancer Res. 2020 Sep 30. pii: 1078-0432.CCR-20-1068.
    PubMed     Abstract available


  74. ISHAK CA, De Carvalho DD
    DNA methylation profiling of premalignant lesions as a path to ovarian cancer early detection.
    Clin Cancer Res. 2020 Sep 28. pii: 1078-0432.CCR-20-3331.
    PubMed     Abstract available


  75. JIN ZH, Tsuji AB, Degardin M, Sugyo A, et al
    Radiotheranostic Agent (64)Cu-cyclam-RAFT-c(-RGDfK-)4 for Management of Peritoneal Metastasis in Ovarian Cancer.
    Clin Cancer Res. 2020 Sep 15. pii: 1078-0432.CCR-20-1205.
    PubMed     Abstract available


  76. JORDAN K, Sikora MJ, Slansky JE, Minic A, et al
    The capacity of the ovarian cancer tumor microenvironment to integrate inflammation signaling conveys a shorter disease-free interval.
    Clin Cancer Res. 2020 Sep 14. pii: 1078-0432.CCR-20-1762.
    PubMed     Abstract available


    August 2020
  77. DA SILVA DM, Enserro DM, Mayadev J, Skeate JG, et al
    Immune activation in patients with locally advanced cervical cancer treated with ipilimumab following definitive chemoradiation (GOG-9929).
    Clin Cancer Res. 2020 Aug 18. pii: 1078-0432.CCR-20-0776.
    PubMed     Abstract available


    July 2020
  78. MORONEY JW, Powderly J, Lieu CH, Bendell JC, et al
    Safety and Clinical Activity of Atezolizumab Plus Bevacizumab in Patients with Ovarian Cancer: A Phase Ib Study.
    Clin Cancer Res. 2020 Jul 28. pii: 1078-0432.CCR-20-0477.
    PubMed     Abstract available


  79. OZA AM, Estevez-Diz MDP, Grischke EM, Hall M, et al
    A biomarker-enriched, randomized Phase II trial of adavosertib (AZD1775) plus paclitaxel and carboplatin for women with platinum-sensitive TP53-mutant ovarian cancer.
    Clin Cancer Res. 2020 Jul 1. pii: 1078-0432.CCR-20-0219.
    PubMed     Abstract available


    May 2020
  80. LHEUREUX S, Oaknin A, Garg S, Bruce JP, et al
    EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression.
    Clin Cancer Res. 2020 May 22. pii: 1078-0432.CCR-19-4121.
    PubMed     Abstract available


  81. JI JX, Cochrane DR, Tessier-Cloutier B, Chen SY, et al
    Arginine depletion therapy with ADI-PEG20 limits tumor growth in argininosuccinate synthase deficient ovarian cancer, including small cell carcinoma of the ovary, hypercalcemic type.
    Clin Cancer Res. 2020 May 14. pii: 1078-0432.CCR-19-1905.
    PubMed     Abstract available


  82. LAMPERT EJ, Zimmer AS, Padget MR, Cimino-Mathews A, et al
    Combination of PARP inhibitor olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase 2 study.
    Clin Cancer Res. 2020 May 12. pii: 1078-0432.CCR-20-0056.
    PubMed     Abstract available


    April 2020
  83. LI J, Pan C, Boese AC, Kang J, et al
    DGKA provides platinum resistance in ovarian cancer through activation of cJUN-WEE1 signaling.
    Clin Cancer Res. 2020 Apr 27. pii: 1078-0432.CCR-19-3790.
    PubMed     Abstract available


  84. CHOI YJ, Hur SY, Kim TJ, Hong SR, et al
    A Phase II, Prospective, Randomized, Multicenter, Open-Label Study of GX-188E, an HPV DNA Vaccine, in Patients with Cervical Intraepithelial Neoplasia 3.
    Clin Cancer Res. 2020;26:1616-1623.
    PubMed     Abstract available


    March 2020
  85. YOU B, Robelin P, Tod M, Louvet C, et al
    CA-125 ELIMination rate constant K (KELIM) Is A Marker Of Chemosensitivity In Patients With Ovarian Cancer: Results from the Phase II CHIVA trial.
    Clin Cancer Res. 2020 Mar 24. pii: 1078-0432.CCR-20-0054.
    PubMed     Abstract available


    February 2020
  86. HARRIS RS, Serebrenik AA, Argyris P, Jarvis MC, et al
    The DNA cytosine deaminase APOBEC3B is a molecular determinant of platinum responsiveness in clear cell ovarian cancer.
    Clin Cancer Res. 2020 Feb 14. pii: 1078-0432.CCR-19-2786.
    PubMed     Abstract available


    January 2020
  87. CASEY RT, McLean MA, Challis BG, McVeigh TP, et al
    Fumarate Metabolic Signature for the Detection of Reed Syndrome in Humans.
    Clin Cancer Res. 2020;26:391-396.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Gynecology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: